Best time to buy Celgene, Vertex & more

12:17 PM ET Fri, 27 June 2014

The biotech ETF soared 67 percent in 2013, but has since been bumpy. Discussing winning and losing stocks in the industry, with Mark Schoenebaum, ISI pharma/biotech analyst.